Journal Scans
Severe Clinical Toxicities Are Correlated With Survival in Patients With Advanced Renal Cell Carcinoma Treated With Sunitinib and Sorafenib
TKI-Related Toxicities Associated With Improved Survival in RCC
F Di Fiore, O Rigal, C Menager, P Michel, C Pfister
20111106
2011 Dec 6
Br J Cancer
Severe Clinical Toxicities Are Correlated With Survival in Patients With Advanced Renal Cell Carcinoma Treated With Sunitinib and Sorafenib
Br J Cancer. 2011 Dec 6;105(12):1811-1813, F Di Fiore, O Rigal, C Menager, P Michel, C Pfister
TAKE-HOME MESSAGE
Abstract
Abstract
Background: In advanced renal cell carcinoma (RCC), sunitinib and sorafenib tyrosine kinase inhibitors (TKI) are associated with several clinical side effects, with no definitive established data concerning their clinical impact.Methods: From June 2006 to June 2008, main clinical TKI-induced toxicities, including digestive, cardiac, dermatologic and asthenia were retrospectively collected using the NCI-CTC version 3.0 in patients treated with TKI for an RCC.Results: The median overall survival was...
